Use of electronic medical records to monitor the safe and effective prescribing of medicinal cannabis: is it feasible?
Christine M. Hallinan
A B C * , Jane M. Gunn B , Yining Qian C and Yvonne A. Bonomo B D
+ Author Affiliations
- Author Affiliations
A Department of General Practice, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences of the University of Melbourne, Level 2, 780 Elizabeth Street, Melbourne, Vic. 3004, Australia.
B Faculty of Medicine, Dentistry and Health Sciences of the University of Melbourne, Level 2, Alan Gilbert Building, Grattan Street, Parkville, Vic. 3010, Australia.
C Health and Biomedical Research Information Technology Unit (HaBIC R2), Faculty of Medicine, Dentistry and Health Sciences of the University of Melbourne, Level 2, 780 Elizabeth Street, Melbourne, Vic. 3004, Australia.
D Department of Addiction Medicine, St Vincent’s Hospital, Fitzroy, Vic. 3065, Australia.
* Correspondence to: hallinan@unimelb.edu.au
Australian Journal of Primary Health 28(6) 564-572 https://doi.org/10.1071/PY22054
Submitted: 8 March 2022 Accepted: 17 June 2022 Published: 5 August 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of La Trobe University. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)
Abstract
Background: General practitioners are well positioned to contribute to the pharmacovigilance of medical cannabis via the general practice electronic medical record (EMR). The aim of this research is to interrogate de-identified patient data from the Patron primary care data repository for reports of medicinal cannabis to ascertain the feasibility of using EMRs to monitor medicinal cannabis prescribing in Australia.
Methods: EMR rule-based digital phenotyping of 1 164 846 active patients from 109 practices was undertaken to investigate reports of medicinal cannabis use from September 2017 to September 2020.
Results: Eighty patients with 170 prescriptions of medicinal cannabis were identified in the Patron repository. Reasons for prescription included anxiety, multiple sclerosis, cancer, nausea, and Crohn’s disease. Nine patients showed symptoms of a possible adverse event, including depression, motor vehicle accident, gastrointestinal symptoms, and anxiety.
Conclusions: The recording of medicinal cannabis effects in the patient EMR provides potential for medicinal cannabis monitoring in the community. This is especially feasible if monitoring were to be embedded into general practitioner workflow.
Keywords: medication systems, electronic medical records, medicinal cannabis, patient safety, pharmacovigilance, physicians’ practice patterns, primary health care, public health: practice, safety management.
References
Abuhasira R, Schleider LB-L, Mechoulam R, Novack V (2018) Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine 49, 44–50.| Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.Crossref | GoogleScholarGoogle Scholar |
Agarwal V, Podchiyska T, Banda JM, Goel V, Leung TI, Minty EP, Sweeney TE, Gyang E, Shah NH (2016) Learning statistical models of phenotypes using noisy labeled training data. Journal of the American Medical Informatics Association 23, 1166–1173.
| Learning statistical models of phenotypes using noisy labeled training data.Crossref | GoogleScholarGoogle Scholar |
Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, Lindblad AJ, Korownyk C, Kolber MR (2018) Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Canadian Family Physician Medecin de Famille Canadien 64, e78–e94.
Banda JM, Seneviratne M, Hernandez-Boussard T, Shah NH (2018) Advances in electronic phenotyping: from rule-based definitions to machine learning models. Annual Review of Biomedical Data Science 1, 53–68.
| Advances in electronic phenotyping: from rule-based definitions to machine learning models.Crossref | GoogleScholarGoogle Scholar |
Banerjee R, Erridge S, Salazar O, Mangal N, Couch D, Pacchetti B, Sodergren MH (2022) Real world evidence in medical cannabis research. Therapeutic Innovation & Regulatory Science 56, 8–14.
| Real world evidence in medical cannabis research.Crossref | GoogleScholarGoogle Scholar |
Boyle D, Sanci L, Emery J, Gunn J, Hocking JS, Manski-Nankervis J-A, Canaway R (2019) Patron primary care research data repository. (University of Melbourne). Dataset. Dataset. Available at https://medicine.unimelb.edu.au/school-structure/general-practice/engagement/data-for-decisions [Accessed 15 July 2022]
Charles-Smith LE, Reynolds TL, Cameron MA, Conway M, Lau EHY, Olsen JM, Pavlin JA, Shigematsu M, Streichert LC, Suda KJ, Corley CD (2015) Using social media for actionable disease surveillance and outbreak management: a systematic literature review. PLoS ONE 10, e0139701
| Using social media for actionable disease surveillance and outbreak management: a systematic literature review.Crossref | GoogleScholarGoogle Scholar |
Currow DC, Rowett D, Doogue M, To THM, Abernethy AP (2012) An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. Journal of Palliative Medicine 15, 282–286.
| An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice.Crossref | GoogleScholarGoogle Scholar |
Dal Pan GJ (2014) Ongoing challenges in pharmacovigilance. Drug Safety 37, 1–8.
| Ongoing challenges in pharmacovigilance.Crossref | GoogleScholarGoogle Scholar |
de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E (2020) Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis. Epilepsy & Behavior 102, 106635
| Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |
Dhruva SS, Ross JS, Desai NR (2018) Real-world evidence: promise and peril for medical product evaluation. P & T: A Peer-Reviewed Journal for Formulary Management 43, 464–472.
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun J-D, Krumholz HM, Ross JS (2017) Postmarket safety events among novel therapeutics approved by the US food and drug administration between 2001 and 2010. JAMA 317, 1854–1863.
| Postmarket safety events among novel therapeutics approved by the US food and drug administration between 2001 and 2010.Crossref | GoogleScholarGoogle Scholar |
Fernholm R, Arvidsson E, Wettermark B (2019) Financial incentives linked to quality improvement projects in Swedish primary care: a model for improving quality of care. BMJ Open Quality 8, e000402
| Financial incentives linked to quality improvement projects in Swedish primary care: a model for improving quality of care.Crossref | GoogleScholarGoogle Scholar |
Freeman TP, Hindocha C, Green SF, Bloomfield MAP (2019) Medicinal use of cannabis based products and cannabinoids. BMJ 365, l1141
| Medicinal use of cannabis based products and cannabinoids.Crossref | GoogleScholarGoogle Scholar |
Hallinan (2019) Does the removal of financial incentives from Australian general practices affect immunisation rates? PhD thesis, Minerva Access, Medicine, Dentistry & Health Science, Melbourne Medical School, The University of Melbourne. Available at http://hdl.handle.net/11343/233864 [Accessed 15 July 2022]
Hallinan CM, Gunn JM, Bonomo YA (2021) Implementation of medicinal cannabis in Australia: innovation or upheaval? Perspectives from physicians as key informants, a qualitative analysis. BMJ Open 11, e054044
| Implementation of medicinal cannabis in Australia: innovation or upheaval? Perspectives from physicians as key informants, a qualitative analysis.Crossref | GoogleScholarGoogle Scholar |
Hallinan CM, Eden E, Graham M, Greenwood L-M, Mills J, Popat A, Truong L, Bonomo Y (2022a) Over the counter low-dose cannabidiol: a viewpoint from the ACRE Capacity Building Group. Journal of Psychopharmacology 36, 661–665.
| Over the counter low-dose cannabidiol: a viewpoint from the ACRE Capacity Building Group.Crossref | GoogleScholarGoogle Scholar |
Hallinan CM, Habibabadi SK, Bonomo YA, Conway M (2022b) Social media discourse and search engine queries on cannabis as a medicine cannabis as a medicine: a systematic approach. PLOS-One
Health Direct Australia (2022) National Health Services Directory. (Health Direct Australia). Available at https://about.healthdirect.gov.au/nhsd [Accessed 10 April 2022]
Hong N, Wen A, Shen F, Sohn S, Liu S, Liu H, Jiang G (2018) Integrating structured and unstructured EHR data using an FHIR-based type system: a case study with medication data. AMIA Summits on Translational Science Proceedings. pp. 74–83.
Huckvale K, Venkatesh S, Christensen H (2019) Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety. npj Digital Medicine 2, 88
| Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety.Crossref | GoogleScholarGoogle Scholar |
Hunter B, Biezen R, Alexander K, Lumsden N, Hallinan C, Wood A, McMorrow R, Jones J, Nelson C, Manski-Nankervis J-A (2020) Future Health Today: codesign of an electronic chronic disease quality improvement tool for use in general practice using a service design approach. BMJ Open 10, e040228
| Future Health Today: codesign of an electronic chronic disease quality improvement tool for use in general practice using a service design approach.Crossref | GoogleScholarGoogle Scholar |
Kurlyandchik I, Tiralongo E, Schloss J (2021) Safety and efficacy of medicinal Cannabis in the treatment of fibromyalgia: a systematic review. The Journal of Alternative and Complementary Medicine 27, 198–213.
| Safety and efficacy of medicinal Cannabis in the treatment of fibromyalgia: a systematic review.Crossref | GoogleScholarGoogle Scholar |
Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold J, Benson M, Mcgregor I (2020) Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal 17, 37
| Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18).Crossref | GoogleScholarGoogle Scholar |
MacCallum CA, Lo LA, Boivin M (2021) “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. European Journal of Internal Medicine 89, 10–18.
| “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations.Crossref | GoogleScholarGoogle Scholar |
Pawliuk C, Chau B, Rassekh SR, McKellar T, Siden HH (2021) Efficacy and safety of paediatric medicinal cannabis use: a scoping review. Paediatrics & Child Health 26, 228–233.
| Efficacy and safety of paediatric medicinal cannabis use: a scoping review.Crossref | GoogleScholarGoogle Scholar |
Pierce CE, de Vries ST, Bodin-Parssinen S, Härmark L, Tregunno P, Lewis DJ, Maskell S, Van Eemeren R, Ptaszynska-Neophytou A, Newbould V, Dasgupta N, Wisniewski AFZ, Gama S, Mol PGM (2019) Recommendations on the use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Safety 42, 477–489.
| Recommendations on the use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR.Crossref | GoogleScholarGoogle Scholar |
Richesson RL, Hammond WE, Nahm M, Wixted D, Simon GE, Robinson JG, Bauck AE, Cifelli D, Smerek MM, Dickerson J, Laws RL, Madigan RA, Rusincovitch SA, Kluchar C, Califf RM (2013) Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory. Journal of the American Medical Informatics Association 20, e226–e231.
| Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory.Crossref | GoogleScholarGoogle Scholar |
Rojas E, Capurro D (2019) ‘Characterization of drug use patterns using process mining and temporal abstraction digital phenotyping.’ (Springer: Cham, Switzerland)
Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J (2020) Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry 20, 24
| Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.Crossref | GoogleScholarGoogle Scholar |
Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L (2018) Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. PAIN 159, 1932–1954.
| Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies.Crossref | GoogleScholarGoogle Scholar |
Sulak D, Saneto R, Goldstein B (2017) The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy & Behavior 70, 328–333.
| The current status of artisanal cannabis for the treatment of epilepsy in the United States.Crossref | GoogleScholarGoogle Scholar |
TGA (2020) Over-the-counter access to low dose cannabidiol. (Therapeutic Goods Administration: Canberra, ACT, Australia) Available at https://www.tga.gov.au/media-release/over-counter-access-low-dose-cannabidiol [Accessed 14 January 2020]
TGA (2021a) About the TGA freedom of information. (Therapeutic Goods Administration: Canberra, ACT, Australia) Available at https://www.tga.gov.au/freedom-information [Accessed 2 October 2021]
TGA (2021b) Database of adverse event notifications - medicines. (Therapeutic Goods Administration: Canberra, ACT, Australia) Available at https://www.tga.gov.au/database-adverse-event-notifications-daen [Accessed 2 October 2021]
TGA (2022a) Medicinal cannabis access data dashboard. (Australian Government Department of Health: Canberra, ACT, Australia) Available at https://www.tga.gov.au/medicinal-cannabis-access-data-dashboard [Accessed 20 August 2021]
TGA (2022b) Medicinal cannabis: role of the TGA. (Therapeutic Goods Administration: Canberra, ACT, Australia) Available at https://www.tga.gov.au/medicinal-cannabis-role-tga [Accessed 8 February 2022]
WHO (2015) ‘WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems.’ (World Health Organisation (WHO): Geneva, Switzerland)
